After Aduhelm probe, 5 burning questions for FDA, Biogen; Covid’s winter surge underway

The FDA has not made clear what it's changed since the Aduhelm debacle, even as it is expected to approve another Alzheimer's drug this week. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   STAT+: In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer's treatments By Damian Garde and Rachel Cohrs STAT The FDA has not made clear what it's changed since the Aduhelm debacle, even as it is expected to approve another Alzheimer’s drug this week. Read More Covid's winter surge is poised to exceed summer peak By Andrew Joseph Mario Tama/Getty Between holidays, winter, low booster uptake, waning immunity and a waxing variant, the coronavirus is finding new chances to infect us. Read More Get care now, pay later?: Health care sees a surge in financing platforms for patients By Katie Palmer Adobe Health providers have started offering payment plans for patients through lenders like Afterpay and Affirm. Read More Sponsored Insight by bluebird bio Longtime advocate Mary Brown reflects on 40 years in sickle cell disease and work that remains Change is long overdue for patients living with sickle cell disease. Mary Brown, President and CEO of the Sickle Cell Disease Foundation shares her perspective on challenges and opportunities during a period of unprecedented attention, investment – and transformation – in sickle cell disease. Her advice? Consistency is key. Consistent communication, consistency in education and awareness, and consistency in insurance coverage can lead to greater progress and positive impact for the sickle cell disease community. Read more from Mary Brown. STAT+: 3 trends to watch in hospitals and health insurance in 2023 By Bob Herman and Tara Bannow Christine Kao/STAT STAT’s business reporters will be paying attention to three hospital and insurance trends next year. Read about them here. Read More STAT+: The biotech scorecard for the first quarter: 19 stock-moving events to watch By Adam Feuerstein Ryan Pierse/Getty Images Drugs for Alzheimer's, psychosis, sickle cell disease, and glioma in children are expected to hit pivotal marks. Read More Paying research participants — a lot — may be a key to increasing diversity in studies By Usha Lee McFarling Adobe Offering $100 widened disparities in study enrollment, but a $500 incentive closed the participation gap completely. Read More Priorities pile up for HHS, FDA, CMS, NIH, and other health agencies By Sarah Owermohle Alex Brandon/AP Officials have promised reforms in food, drug, and public health agencies and are racing to fix pandemic-exposed cracks in health care. Read More Opinion: Better information on sexual orientation and gender identity is needed to improve LGBTQ+ health By Matthew Schabath and C.K. Wang ROBYN BECK/AFP via Getty Images The dearth of data on sexual orientation and gender identity has kept the LGBTQ+ population largely invisible to health care researchers. Read More Tuesday, January 3, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser